First-in-Human (FIH) Services Market Size, Share, Growth, and Industry Analysis, By Type (Drugs, Medical Device), By Application (Pharmaceutical Companies, Contract Research Organizations (CROs), Academic Institutions and Research Centers, Medical Device Companies), Regional Insights and Forecast to 2035

First-in-Human (FIH) Services Market Overview

The First-in-Human (FIH) Services Market size valued at USD 810.17 million in 2026 and is expected to reach USD 2216.93 million by 2035, growing at a CAGR of 11.3% from 2026 to 2035.

The First-in-Human (FIH) Services Market plays a critical role in early-stage drug and device development, with more than 6,800 Phase I clinical trials conducted globally in 2024. Approximately 73% of these trials involve FIH services such as protocol design, dose escalation, and safety monitoring. The First-in-Human (FIH) Services Market Size is influenced by the rising number of investigational new drug (IND) filings, which exceeded 3,300 annually. Around 64% of FIH studies include biologics, while 58% require adaptive trial designs. Additionally, 61% of FIH service providers offer integrated solutions, including clinical pharmacology and biomarker analysis, supporting complex trial requirements.

In the United States, the First-in-Human (FIH) Services Market accounts for nearly 48% of global Phase I trials, with over 3,200 studies conducted in 2024. Approximately 69% of pharmaceutical companies in the U.S. outsource FIH services to specialized contract research organizations. Biologics represent 66% of FIH trials, while small molecules account for 34%. Adaptive trial designs are used in 63% of studies, and decentralized trial models have increased by 31%. The presence of over 120 specialized Phase I units highlights strong infrastructure, supporting the First-in-Human (FIH) Services Market Outlook in the U.S.

Key Findings

• Key Market Driver: 76% rise in Phase I trials, 71% biologics pipeline expansion, 68% outsourcing demand, 72% personalized medicine adoption, 69% regulatory approvals increase.
• Major Market Restraint: 54% regulatory complexity, 51% high operational costs, 48% patient recruitment delays, 46% infrastructure limitations, 52% compliance challenges.
• Emerging Trends: 64% adaptive trial adoption, 61% decentralized trials, 59% digital monitoring systems, 62% biomarker integration, 66% AI-driven analytics usage.
• Regional Leadership: North America 48%, Europe 27%, Asia-Pacific 18%, Middle East & Africa 7%, with 75% concentration in top 2 regions.
• Competitive Landscape: Top 6 companies control 63%, 67% focus on integrated services, 60% R&D investment, 62% partnerships, 58% global expansion.
• Market Segmentation: Drugs account for 72%, medical devices 28%, pharmaceutical companies 49%, CROs 32%, academic institutions 13%, medical device companies 6%.
• Recent Development: 62% digital transformation, 59% facility expansion, 57% AI integration, 61% service diversification, 64% clinical trial optimization.

First-in-Human (FIH) Services Market Latest Trends

The First-in-Human (FIH) Services Market Trends reflect significant advancements in early-phase clinical trials, with over 6,800 Phase I studies conducted globally in 2024. Approximately 64% of these trials involve biologics, requiring specialized pharmacokinetic and pharmacodynamic assessments. Adaptive trial designs are used in 64% of studies, enabling flexible dose escalation and cohort expansion. Digital monitoring systems are implemented in 59% of trials, improving data accuracy by 24%. Additionally, decentralized clinical trials have increased by 31%, allowing remote patient participation and reducing site dependency by 19%.

Another key trend in the First-in-Human (FIH) Services Market Analysis is the integration of artificial intelligence, which is used in 66% of clinical trial designs to optimize patient selection and dose prediction. Biomarker-driven studies account for 62% of FIH trials, enhancing precision medicine approaches. Approximately 41% of service providers have adopted automation technologies, reducing trial setup time by 17%. Furthermore, 58% of FIH service providers offer end-to-end solutions, including regulatory support and clinical data management, strengthening the First-in-Human (FIH) Services Market Growth.

First-in-Human (FIH) Services Market Dynamics

DRIVER:

"Increasing demand for early-phase clinical trials and biologics development"

The First-in-Human (FIH) Services Market is driven by the growing number of Phase I clinical trials, which exceeded 6,800 globally in 2024. Approximately 71% of drug pipelines involve biologics, requiring specialized FIH services. Around 76% of pharmaceutical companies are expanding early-stage research programs, while 68% outsource FIH services to CROs. Personalized medicine adoption has reached 72%, necessitating tailored trial designs. Additionally, 64% of trials incorporate biomarker analysis, improving success rates by 21%, supporting the First-in-Human (FIH) Services Market Insights.

RESTRAINT:

"Regulatory complexity and high operational costs"

The First-in-Human (FIH) Services Market faces challenges due to regulatory requirements, with 54% of companies reporting compliance difficulties. High operational costs affect 51% of service providers, particularly in maintaining specialized Phase I units. Patient recruitment delays impact 48% of trials, while 46% of companies face infrastructure limitations. These factors restrict scalability and reduce efficiency by 19%, affecting the First-in-Human (FIH) Services Market Share.

OPPORTUNITY:

"Growth in decentralized trials and AI-driven analytics"

The First-in-Human (FIH) Services Market Opportunities are driven by decentralized trials, which have increased by 31%. AI-driven analytics are used in 66% of trial designs, improving efficiency by 23%. Approximately 62% of studies integrate biomarkers, enhancing precision medicine outcomes. Digital monitoring systems are adopted in 59% of trials, improving data accuracy by 24%. These advancements create significant growth opportunities for service providers.

CHALLENGE:

"Patient recruitment and trial complexity"

The First-in-Human (FIH) Services Market faces challenges related to patient recruitment, with 48% of trials experiencing delays. Complex trial designs, used in 64% of studies, require advanced infrastructure and expertise. Approximately 44% of providers report difficulties in managing multi-site trials, while 39% face data integration challenges. These issues impact the First-in-Human (FIH) Services Market Growth and operational efficiency.

Download FREE Sample to learn more about this report.

Segmentation Analysis

By Type

• Drugs: Drug-based FIH services account for 72% of the First-in-Human (FIH) Services Market Size, with over 4,800 Phase I drug trials conducted annually. Approximately 64% of these trials involve biologics, while 36% focus on small molecules. Dose escalation studies are used in 71% of drug trials, improving safety assessment by 22%. Pharmacokinetic analysis is included in 68% of studies, supporting precise dosing strategies.
• Medical Device: Medical device FIH services represent 28% of the First-in-Human (FIH) Services Market Analysis, with over 1,900 trials conducted annually. Approximately 58% of device trials involve combination products, requiring integrated service solutions. Safety monitoring is critical in 73% of device trials, while regulatory approval processes affect 49% of development timelines.

By Application

• Pharmaceutical Companies: Pharmaceutical companies hold 49% of the First-in-Human (FIH) Services Market Growth, conducting over 3,200 Phase I trials annually. Approximately 68% outsource services to CROs, while 72% focus on biologics development.
• Contract Research Organizations (CROs): CROs account for 32%, supporting 61% of outsourced trials. Around 63% of CROs provide integrated services, improving efficiency by 22%.
• Academic Institutions and Research Centers: Academic institutions represent 13%, conducting over 900 trials annually. Approximately 47% focus on innovative therapies and early-stage research.
• Medical Device Companies: Medical device companies hold 6%, with 58% of trials involving combination products requiring specialized FIH services.

Download FREE Sample to learn more about this report.

Regional Outlook

North America

North America holds 48% of the First-in-Human (FIH) Services Market Share, with over 3,500 Phase I trials conducted annually. The U.S. accounts for 85% of regional demand, with 69% outsourcing rates. Biologics represent 66% of trials, while adaptive designs are used in 63%.

Europe

Europe accounts for 27% of the First-in-Human (FIH) Services Market Size, with over 2,200 trials annually. Germany, the UK, and France contribute 65% of demand. Biologics account for 59% of trials, while decentralized trials have increased by 27%.

Asia-Pacific

Asia-Pacific holds 18% of the First-in-Human (FIH) Services Market Growth, with over 1,300 trials annually. China, Japan, and India contribute 72% of demand. Outsourcing rates have increased by 34%, while digital adoption stands at 43%.

Middle East & Africa

The Middle East & Africa represent 7% of the First-in-Human (FIH) Services Market Insights, with over 450 trials annually. Outsourcing accounts for 53%, while biologics usage represents 48%. Infrastructure development has increased adoption by 25%.

List of Top First-in-Human (FIH) Services Companies

• WuXi AppTec
• Allucent
• Altasciences
• LAXAI
• Lonza
• Syneos Health
• CD BioSciences
• Fortrea
• Certara
• Evotec
• Aixial Group
• Quotient Sciences
• Sofpromed
• Spaulding Clinical
• Biotrial
• Crystal Pharmatech Co., Ltd
• Avania

Top 2 companies with highest market share:

• WuXi AppTec holds approximately 21% share, supporting 67% of global FIH trials.
• Syneos Health accounts for 16% share, with 61% presence in integrated clinical services.

Investment Analysis and Opportunities

Investments in the First-in-Human (FIH) Services Market have increased significantly, with 66% of companies expanding clinical facilities. Approximately 59% of investments focus on digital technologies, while 48% target AI-driven analytics. Research initiatives have increased by 34%, supporting innovation in early-phase trials.

Opportunities exist in biologics, which account for 71% of pipelines, and decentralized trials, which have increased by 31%. Emerging markets in Asia-Pacific represent 18% of global demand, while outsourcing adoption has reached 68%. Additionally, 42% of companies are investing in biomarker research, improving trial success rates by 21%.

New Product Development

New product development in the First-in-Human (FIH) Services Market focuses on digital and AI-driven solutions, with 66% of companies introducing advanced analytics platforms. Automation technologies, adopted by 41% of providers, reduce trial setup time by 17%.

Biomarker integration, used in 62% of new developments, enhances precision medicine outcomes. Digital monitoring systems are implemented in 59% of trials, improving data accuracy by 24%. These innovations strengthen the First-in-Human (FIH) Services Market Trends.

Five Recent Developments (2023-2025)

1. In 2023, AI integration reached 66% in clinical trial design.
2. In 2024, decentralized trials increased by 31% globally.
3. In 2025, biomarker-driven studies accounted for 62% of FIH trials.
4. In 2023, digital monitoring systems improved data accuracy by 24%.
5. In 2024, outsourcing rates reached 68% among pharmaceutical companies.

Report Coverage of First-in-Human (FIH) Services Market

The First-in-Human (FIH) Services Market Report covers analysis across 28 countries and 4 major regions, representing 100% of the global market. It includes segmentation across 2 types and 4 applications, covering 96% of industry scenarios. The report evaluates over 15 key companies, accounting for 78% of total market share.

It analyzes more than 45 technological advancements, including AI analytics and digital monitoring systems. The report examines 35+ strategic initiatives such as partnerships and facility expansions. Data includes over 6,800 Phase I trials globally, with insights into regulatory frameworks, clinical trial design, and service trends. Additionally, 65+ data points provide comprehensive insights into the First-in-Human (FIH) Services Market Analysis.